(+)-Catechin hydrate

(+)-Catechin hydrate inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM.

Product information

CAS Number: 225937-10-0

Molecular Weight: 308.28

Formula: C15H16O7

Chemical Name: (2R, 3S)-2-(3, 4-dihydroxyphenyl)-3, 4-dihydro-2H-chromene-3, 5, 7-triol;hydrate

Smiles: O.O[C@H]1CC2=C(C=C(O)C=C2O)O[C@@H]1C1=CC(O)=C(O)C=C1

InChiKey: OFUMQWOJBVNKLR-NQQJLSKUSA-N

InChi: InChI=1S/C15H14O6.H2O/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7;/h1-5,13,15-20H,6H2;1H2/t13-,15+;/m0./s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 50 mg/mL (Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

(+)-Catechin exhibits >95% inhibitory activity at 70 μg/mL against cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. A dose-dependent reduction in color is observed after 24 hours of treatment with (+)-Catechin, and 54.76% of the cells are dead at the highest concentration of (+)-Catechin tested (160 μg/mL) whereas the IC50 of (+)-Catechin is achieved at 127.62 μg/mL (+)-Catechin. A dose- and time-dependent increase in the induction of apoptosis is observed when MCF-7 cells are treated with (+)-Catechin. When compare to the control cells at 24 hours, 40.7 and 41.16% of the cells treated with 150 μg/mL and 300 μg/mL (+)-Catechin, respectively, undergo apoptosis. The expression levels of Caspase-3, -8, and -9 and p53 in MCF-7 cells treated with 150 μg/mL (+)-Catechin for 24 h increase by 5.81, 1.42, 3.29, and 2.68 fold, respectively, as compare to the levels in untreated control cells.

In Vivo:

Animals treated with (+)-Catechin at the lowest tested dose, i.e., 50 mg/kg, p.o. have spent comparatively more time in exploring the novel object in the choice trial, however, the difference is not statistically significant. (+)-Catechin prevents the time-induced episodic memory deficits in a dose-dependent manner, the most effective being 200 mg/kg, p.o.. Treatment with (+)-Catechin prevents the rise in MPO level compare to DOX alone treatment group (21.98±9.44 and 36.76±4.39% in the hippocampus and the frontal cortex respectively).

Products are for research use only. Not for human use.